Abbott completes AMO acquisition

Article

Abbott Laboratories has completed its acquisition of Advanced Medical Optics (AMO), paying $1.24 billion for 83% of the fully-diluted stock and assuming around $1.4 billion of AMO's long-term debt.

Abbott Laboratories has completed its acquisition of Advanced Medical Optics (AMO), paying $1.24 billion for 83% of the fully-diluted stock and assuming around $1.4 billion of AMO's long-term debt.

Scott Stoffel, director of financial and litigation communications at Abbott remarked, "Our four major business divisions all delivered double-digit percentages of growth during the past year, resulting in 14% growth of our full-year 2008 sales. This leaves us in a very confident position for purchasing AMO, which is a global leader in eye-care devices."

As a subsidiary of Abbott, AMO will now be known as Abbott Medical Optics. The sales representatives, customer service team and pricing and ordering structure will remain the same.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
© 2025 MJH Life Sciences

All rights reserved.